Asthma - Adults
|
Most Recent Report |
Past Reports |
Rate: 17%
* 2012 Report (7/1/2011-6/30/2012 DOS) (* Avg: 30%)
|
| Rate: 5%
* 2011 Report (7/1/2010-6/30/2011 DOS) (* Avg: 16%)
|
|
|
Colorectal Cancer
|
Most Recent Report |
Past Reports |
Rate: 68%
* 2012 Report (7/1/2011-6/30/2012 DOS) (* Avg: 68%)
|
| Rate: 64%
* 2011 Report (7/1/2010-6/30/2011 DOS) (* Avg: 64%)
|
|
|
Response at 6 Months |
Most Recent Report |
Rate: 5%
* July 01 2011 to June 30 2012 (* Avg: 12%)
|
| Rate: 4%
* July 01 2010 to June 30 2011 (* Avg: 10%)
|
|
Response at 12 Months |
Most Recent Report |
Rate: 2%
* Jan 1 2011 - Dec 31 2011 (* Avg: 9%)
|
| Rate: 0%
* Jan 1 2010 - Dec 31 2010 (* Avg: 9%)
|
|
Remission at 6 Months |
Most Recent Report |
Rate: 2%
* July 01 2011 to June 30 2012 (* Avg: 7%)
|
| Rate: 2%
* July 01 2010 to June 30 2011 (* Avg: 6%)
|
|
Remission at 12 Months |
Most Recent Report |
Rate: 0%
* Jan 1 2011 - Dec 31 2011 (* Avg: 5%)
|
| Rate: 0%
* Jan 1 2010 - Dec 31 2010 (* Avg: 5%)
|
|
Utilization of the PHQ-9 |
Most Recent Report |
Legend  | Clinic Average |  | State Average |
|
Diabetes
|
Most Recent Report |
Past Reports |
Rate: 54%
* 2013 Report (2012 DOS) (* Avg: 38%)
|
| Rate: 53%
* 2012 Report (2011 DOS) (* Avg: 38%)
| Rate: 52%
* 2011 Report (2010 DOS) (* Avg: 37%)
| Rate: 57%
* 2010 Report (2009 DOS) (* Avg: 25%)
|
|
|
Diabetes - Blood Pressure
|
Most Recent Report |
Past Reports |
Rate: 93%
* 2013 Report (2012 DOS) (* Avg: 84%)
|
| Rate: 92%
* 2012 Report (2011 DOS) (* Avg: 84%)
| Rate: 89%
* 2011 Report (2010 DOS) (* Avg: 83%)
| Rate: 86%
* 2010 Report (2009 DOS) (* Avg: 58%)
|
|
|
Diabetes - LDL Control
|
Most Recent Report |
Past Reports |
Rate: 73%
* 2013 Report (2012 DOS) (* Avg: 62%)
|
| Rate: 75%
* 2012 Report (2011 DOS) (* Avg: 62%)
| Rate: 73%
* 2011 Report (2010 DOS) (* Avg: 60%)
| Rate: 78%
* 2010 Report (2009 DOS) (* Avg: 57%)
|
|
|
Diabetes - HbA1c Control
|
Most Recent Report |
Past Reports |
Rate: 85%
* 2013 Report (2012 DOS) (* Avg: 74%)
|
| Rate: 83%
* 2012 Report (2011 DOS) (* Avg: 75%)
| Rate: 84%
* 2011 Report (2010 DOS) (* Avg: 75%)
| Rate: 86%
* 2010 Report (2009 DOS) (* Avg: 72%)
|
|
|
Diabetes - Tobacco-free
|
Most Recent Report |
Past Reports |
Rate: 83%
* 2013 Report (2012 DOS) (* Avg: 84%)
|
| Rate: 82%
* 2012 Report (2011 DOS) (* Avg: 84%)
| Rate: 85%
* 2011 Report (2010 DOS) (* Avg: 83%)
| Rate: 88%
* 2010 Report (2009 DOS) (* Avg: 83%)
|
|
|
Diabetes - Daily Aspirin Use
|
Most Recent Report |
Past Reports |
Rate: 100%
* 2013 Report (2012 DOS) (* Avg: 99%)
|
| Rate: 100%
* 2012 Report (2011 DOS) (* Avg: 99%)
| Rate: 100%
* 2011 Report (2010 DOS) (* Avg: 99%)
| Rate: 99%
* 2010 Report (2009 DOS) (* Avg: 86%)
|
|
|
Health Information Technology |
|
Vascular Disease
|
Most Recent Report |
Past Reports |
Rate: 53%
* 2013 Report (2012 DOS) (* Avg: 49%)
|
| Rate: 50%
* 2012 Report (2011 DOS) (* Avg: 49%)
| Rate: 45%
* 2011 Report (2010 DOS) (* Avg: 40%)
| Rate: 54%
* 2010 Report (2009 DOS) (* Avg: 34%)
|
|
|
Vascular Disease - Blood Pressure
|
Most Recent Report |
Past Reports |
Rate: 86%
* 2013 Report (2012 DOS) (* Avg: 84%)
|
| Rate: 91%
* 2012 Report (2011 DOS) (* Avg: 84%)
| Rate: 75%
* 2011 Report (2010 DOS) (* Avg: 67%)
| Rate: 76%
* 2010 Report (2009 DOS) (* Avg: 58%)
|
|
|
Vascular Disease - LDL Control
|
Most Recent Report |
Past Reports |
Rate: 72%
* 2013 Report (2012 DOS) (* Avg: 67%)
|
| Rate: 78%
* 2012 Report (2011 DOS) (* Avg: 67%)
| Rate: 66%
* 2011 Report (2010 DOS) (* Avg: 65%)
| Rate: 68%
* 2010 Report (2009 DOS) (* Avg: 64%)
|
|
|
Vascular Disease - Tobacco-free
|
Most Recent Report |
Past Reports |
Rate: 75%
* 2013 Report (2012 DOS) (* Avg: 83%)
|
| Rate: 72%
* 2012 Report (2011 DOS) (* Avg: 83%)
| Rate: 72%
* 2011 Report (2010 DOS) (* Avg: 83%)
| Rate: 86%
* 2010 Report (2009 DOS) (* Avg: 81%)
|
|
|
Vascular Disease - Daily Aspirin Use
|
Most Recent Report |
Past Reports |
Rate: 96%
* 2013 Report (2012 DOS) (* Avg: 96%)
|
| Rate: 100%
* 2012 Report (2011 DOS) (* Avg: 95%)
| Rate: 100%
* 2011 Report (2010 DOS) (* Avg: 94%)
| Rate: 97%
* 2010 Report (2009 DOS) (* Avg: 92%)
|
|
|
